Skip to main content
Amplia Therapeutics Limited (ASX:ATX)
Australia flag Australia · Delayed Price · Currency is AUD
0.110
0.00 (0.00%)
At close: Mar 9, 2026

Amplia Therapeutics Revenue

Amplia Therapeutics had revenue of 2.63M AUD in the half year ending September 30, 2025, with 7.44% growth. This brings the company's revenue in the last twelve months to 5.01M, up 46.79% year-over-year. In the fiscal year ending March 31, 2025, Amplia Therapeutics had annual revenue of 3.78M, down -15.03%.

Revenue (ttm)
5.01M
Revenue Growth
+46.79%
P/S Ratio
11.27
Revenue / Employee
n/a
Employees
n/a
Market Cap
56.44M

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Mar 31, 20253.78M-669.04K-15.03%
Mar 31, 20244.45M3.26M274.34%
Mar 31, 20231.19M-793.83K-40.03%
Mar 31, 20221.98M449.80K29.33%
Mar 31, 20211.53M1.50M4,380.44%
Mar 31, 2020 Pro Pro Pro
Mar 31, 2019 Pro Pro Pro
Mar 31, 2018 Pro Pro Pro
Mar 31, 2017 Pro Pro Pro
Mar 31, 2016 Pro Pro Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
Neurizon Therapeutics 5.98M
Proteomics International Laboratories 3.21M
Entropy Neurodynamics 1.58M
EZZ Life Science Holdings 61.40M
Prescient Therapeutics 4.27M
Avecho Biotechnology 1.24M
Radiopharm Theranostics 16.28M
Imugene 3.94M
Revenue Rankings

Amplia Therapeutics News

More News